Simon, Arne; Gröger, Nora; Wilkesmann, Anja; Hasan, Carola; Wiszniewsky, Gertrud; Engelhart, Steffen; Kramer, Michael H; Bode, Udo; Ammann, Roland A; Fleischhack, Gudrun (2006). Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia. International journal of antimicrobial agents, 28(5), pp. 417-22. Amsterdam: Elsevier 10.1016/j.ijantimicag.2006.08.007
Full text not available from this repository.Until now, studies confirming the safety of glycopeptide restriction in the empirical treatment of prolonged fever and neutropenia included only nine children. In an open-label observational study, the use of teicoplanin in paediatric oncology patients was investigated. A period of unrestricted use (2001-2003) was compared with a second period (2004) following implementation of a restrictive treatment guideline. Empirical first-line treatment consisted of piperacillin/tazobactam; in 2004, fosfomycin was added after 72 h as the second-line combination instead of teicoplanin. In total, 213 episodes (n=163 in 2001-2003; n=50 in 2004) managed with teicoplanin or fosfomycin (only 2004) were eligible. Empirical treatment of fever of unknown origin with teicoplanin was reduced by 97%. In 2004, the mean length of stay was 0.4 days shorter, no infection-related death occurred and no vancomycin-resistant enterococci were detected. Restriction of empirical glycopeptides is safe in paediatric cancer patients after first-line treatment with piperacillin/tazobactam. Fosfomycin appears to offer a feasible and cost-saving alternative in second-line combination therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine |
UniBE Contributor: |
Ammann, Roland |
ISSN: |
0924-8579 |
ISBN: |
17046210 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Anette van Dorland |
Date Deposited: |
04 Oct 2013 14:48 |
Last Modified: |
05 Dec 2022 14:14 |
Publisher DOI: |
10.1016/j.ijantimicag.2006.08.007 |
PubMed ID: |
17046210 |
Web of Science ID: |
000242653600008 |
URI: |
https://boris.unibe.ch/id/eprint/20003 (FactScience: 3082) |
Actions (login required)
 |
Edit item |